---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330541"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2026-08-03T20:05:21+00:00"
generated_at: "2026-08-03T20:09:58.511331+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro Q2 revenue $10.9M (+18% YoY); revises 2026 guidance to $48-52M

## Summary
- Q2 revenue $10.9M (+18% YoY); Biologics & Drug Delivery revenue fell 15% to $4.0M.
- Neurosurgery navigation revenue surged 62% to $5.6M on IRRA flow and software.
- Operating expenses rose 51% to $17.0M; cash at $29.4M, down from $45.9M at year-end.
- 2026 revenue guidance revised to $48-52M; company prioritizing clinical capacity and new tech.
- Multiple biopharma partners received positive FDA feedback; expects 10-15 trials enrolling in 18 months.

## SEC filing metadata
- accession: 0001193125-26-330541
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2026-08-03T20:05:21+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/0001193125-26-330541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/clpt-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330541
- JSON: https://secwatch.observer/filing/0001193125-26-330541.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.